May 29, 2024 05:48 AM EDTUpdated May 30, 04:18 AM
R&D

As­traZeneca re­veals ear­ly da­ta for oral PC­SK9, touts PK edge over Mer­ck’s drug

Ayisha Sharma

News Reporter

As­traZeneca has un­veiled the ear­ly ef­fi­ca­cy pro­file of its oral PC­SK9 in­hibitor in pa­tients with high lev­els of “bad” cho­les­terol.

One arm of the Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times